DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0231060 A1 Burdette Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0231060 A1 Burdette Et Al US 2004O231060A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0231060 A1 Burdette et al. (43) Pub. Date: Nov. 25, 2004 (54) METHODS TO ENHANCE THE ACTIVITY Related U.S. Application Data OF LIGNOCELLULOSE-DEGRADING ENZYMES (60) Provisional application No. 60/452,631, filed on Mar. 7, 2003. Provisional application No. 60/498,098, filed (75) Inventors: Jill Burdette, Morrisville, NC (US); on Aug. 27, 2003. Provisional application No. 60/502, Brian Vande Berg, Durham, NC (US); 727, filed on Sep. 12, 2003. Provisional application Brian Carr, Raleigh, NC (US); No. 60/538,334, filed on Jan. 22, 2004. Nicholas B. Duck, Apex, NC (US); Michael G. Koziel, Raleigh, NC (US); Publication Classification Nadine Carozzi, Raleigh, NC (US); Paresma R. Patel, Durham, NC (US) (51) Int. Cl. .................................................. D06M 10/00 (52) U.S. Cl. ............................................................. 8/115.51 Correspondence Address: (57) ABSTRACT ALSTON & BIRD LLP BANK OF AMERICA PLAZA Methods for hydrolyzing lignocellulose are provided, com 101 SOUTH TRYON STREET, SUITE 4000 prising contacting the lignocellulose with at least one chemi CHARLOTTE, NC 28280-4000 (US) cal treatment. Methods for pretreating a lignocellulosic material comprising contacting the material with at least one (73) Assignee: Athenix Corporation, Durham, NC chemical are also provided. Methods for liberating a sub stance Such as an enzyme, a pharmaceutical, or a nutraceu (21) Appl. No.: 10/795,102 tical from plant material are also provided. These methods are more efficient, more economical, and leSS toxic than (22) Filed: Mar. 5, 2004 current methods. Glucose Patent Application Publication Nov. 25, 2004 Sheet 1 of 4 US 2004/0231060 A1 FIG. 1 Patent Application Publication Nov. 25, 2004 Sheet 2 of 4 US 2004/0231060 A1 Sugars, H2O2 Sugars, H2O2 + Cellulase + Xylanase OmM 10mM 20mM 40mM 60mM FIG. 2 Patent Application Publication Nov. 25, 2004 Sheet 3 of 4 US 2004/0231060 A1 100 0.6 O) s C 0.5 V 80 o () E 60 s ?: 0.3 SP 40 (f) 0.2 ge C 20 g 0.1 .2g SS O O O 4 8 12 16 20 24 Time (hr) -A-% H2O2 remaining -- Soluble Sugars FIG. 3 Patent Application Publication Nov. 25, 2004 Sheet 4 of 4 US 2004/0231060 A1 1.6 . 6 1.4 C Wed 1.2 1 0 Stower Sugars 5 0.8 Glucose + Xylose s S 0.6 t is 0.4 0.2 O O 0.2 0.4 0.6 0.8 Growth Media Sugars (%) FIG. 4 US 2004/0231060 A1 Nov. 25, 2004 METHODS TO ENHANCE THE ACTIVITY OF removed in additional processes to allow Subsequent deg LIGNOCELLULOSE-DEGRADING ENZYMES radation of cellulose with enzymes or by a co-fermentation process known as Simultaneous Saccharification and fermen CROSS-REFERENCE TO RELATED tation (SSF). APPLICATIONS 0007. The harsh conditions needed for chemical pretreat 0001. The present application claims the benefit of U.S. ments require expensive reaction vessels, and are energy Provisional Application Serial No. 60/452,631, filed Mar. 7, intensive. Since the chemical treatment occurs at tempera 2003, U.S. Provisional Application No. 60/498,098, filed ture and pH conditions (for example 160° C. and 0.2% Aug. 27, 2003, U.S. Provisional Application No. 60/502, Sulfuric acid at 12 atm. pressure) incompatible with known 727, filed Sep. 12, 2003, and U.S. Provisional Application cellulosic enzymes, and produces compounds that must be No. 60/538,334, filed Jan. 22, 2004, the contents of which removed before fermentation, this process must occur in are herein incorporated by reference in their entirety. Separate reaction vessels from cellulose degradation, and must occur prior to cellulose degradation. Thus, novel FIELD OF THE INVENTION methods that are more compatible with the cellulose degra dation process, that do not generate toxic waste products, 0002 Methods to enhance the production of free Sugars and that require less energy would be desirable. Further, and oligosaccharides from plant material are provided. enzymatic processes that occur in conditions Similar to those used for cellulose degradation would allow development of BACKGROUND OF THE INVENTION co-treatment processes wherein the breakdown of hemicel lulose and cellulose occur in the same reaction vessel, or are 0.003 Plant biomass is comprised of Sugars and repre not separated in the manner in which current pre-treatment Sents the greatest Source of renewable hydrocarbon on earth. processes must be separated from cellulose breakdown and However, this enormous resource is under-utilized because the Sugars are locked in complex polymers. These complex Subsequent processes. In addition, processes that liberate polymers are often referred to collectively as lignocellulose. Sugars from lignocellulose without generating toxic prod SugarS generated from degradation of plant biomass could ucts may provide additional benefits due to the increased provide plentiful, economically competitive feedstocks for accessibility of nutrients present in lignocellulosic material fermentation into chemicals, plastics, and fuels, including Such as proteins, amino acids, lipids, and the like. ethanol as a Substitute for petroleum. 0008 For these reasons, efficient methods are needed for 0004 Commercial ethanol production in the U.S. is cur conversion of lignocellulose to Sugars and fermentation rently carried out in dry mill facilities, converting corn grain feedstockS. to ethanol. However corn grain is expensive, and has other SUMMARY OF INVENTION high value uses, Such as use in livestock feeds, and high 0009 Methods are provided for hydrolyzing lignocellu fructose corn syrups (Wyman, ed. (1999) Handbook On lose with increased efficiency without the need for a harsh Bioethanol. Production, and Utilization. Taylor & Francis, pretreatment. These methods involve a chemical treatment Washington, D.C., p.1). Alternate feedstocks for ethanol of the lignocellulose at mild or moderate conditions to production that allow production at a lower cost, and on a generate a treated lignocellulose, and contacting this treated larger commercial Scale, are desirable. lignocellulose with at least one enzyme capable of hydro 0005 Lignocellulosics such as corn stover, which is lyzing a component of lignocellulose. The chemical treat cheap, abundant, and has no competing markets, would be ment involves contacting lignocellulose with at least one preferred over grain for the production of ethanol. The chemical that acts in combination with enzyme treatment to limiting factor is the complex composition of the Sugar liberate Sugars. polymers. Starch in corn grain is a highly branched, water Soluble polymer that is amenable to enzyme digestion. In 0010 Methods are also provided for pretreating a ligno contrast, the carbohydrates comprising lignocellulosic mate cellulosic material comprising contacting the material with rials. Such as corn Stover are more difficult to digest. These at least one chemical under mild or moderate conditions to carbohydrates are principally found as complex polymers generate a treated lignocellulose. In Some embodiments, the including cellulose, hemicellulose and glucans, which form treated lignocellulose may be further treated with at least the Structural components of plant cell walls and Woody one enzyme capable of hydrolyzing lignocellulose. tissues. Starch and cellulose are both polymers of glucose. 0011 Methods for liberating substances from lignocellu losic material are also encompassed. These methods com 0006 Current processes to release the Sugars in lignocel prise a chemical treatment of the lignocellulosic material lulose involve many Steps. A key Step in the process is a under mild or moderate conditions. In Some embodiments, at harsh pretreatment. The aim of the current industry pretreat least one enzyme capable of hydrolyzing lignocellulose may ment is to increase the accessibility of cellulose to cellulose hydrolyzing enzymes, Such as the cellulase mixture derived be added Subsequent to the chemical treatment. Enzymes, from fermentation of the fungus Trichoderma reesei. Cur pharmaceuticals, and nutraceuticals may be released by rent pretreatment processes involve partial hydrolysis of treating lignocellulosic material by the methods of the lignocellulosic material, Such as corn Stover, in Strong acids invention. In Some embodiments, the lignocellulosic mate or bases under high temperatures and preSSures. Such rial has been engineered to contain the Substance to be chemical pretreatments degrade hemicellulose and/or lignin released. components of lignocellulose to expose cellulose, but also 0012 Chemicals for use in the above methods include create unwanted by-products Such as acetic acid, furfural, Oxidizing agents, denaturants, detergents, organic Solvents, and hydroxymethyl furfural. These products must be bases, or any combination thereof. US 2004/0231060 A1 Nov. 25, 2004 0013 Methods for hydrolyzing lignocellulose compris 0022 Methods for pretreating a lignocellulosic material ing contacting the lignocellulose with an oxidizing agent to comprising contacting the material under mild or moderate generate a treated lignocellulose, and contacting the treated conditions with at least one chemical are also provided. The lignocellulose with at least one enzyme capable of hydro treated lignocellulosic material may be further Subjected to lyzing lignocellulose are also provided. treatment with at least one enzyme capable of hydrolyzing lignocellulose. 0.014 Further provided are methods for hydrolyzing lignocellulose, comprising contacting the lignocellulose 0023. Further provided are methods for liberating a sub with a base
Load more

Recommended publications
  • Characterizing the Roles of ADAM10 and 15 Disintegrins in Prostate Biology and Disease
    Characterizing the roles of ADAM10 and 15 disintegrins in prostate biology and disease by Magdalena M. Grabowska A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Cellular and Molecular Biology) in The University of Michigan 2011 Doctoral Committee: Professor Mark L. Day, Chair Professor James T. Elder Professor Robert S. Fuller Professor Jill A. Macoska Professor Benjamin L. Margolis Dedication To my parents for their unending support ii Acknowledgements I would like to extend a tremendous thank you to my family and friends without whose support this doctoral process would not have been possible. I would also like to thank Derek for being a constant source of support in all aspects of my life. I would like to thank Mark for taking me on as a graduate student and my committee for their commitment to my training. Thank you to the faculty members and administrators of the Cellular and Molecular Biology and the Cancer Biology Programs for your willingness to help with training, letters, funding, and graduate student business as a whole. Finally, I would like to thank collaborators who have provided reagents, resources, expertise, and lab equipment without which my research would not have been possible. Thank you. iii Table of Contents Dedication ............................................................................................................ ii Acknowledgements .............................................................................................. iii List of Figures
    [Show full text]
  • Oleoresins and Naturally Occurring Compounds of Copaifera Genus As
    www.nature.com/scientificreports OPEN Oleoresins and naturally occurring compounds of Copaifera genus as antibacterial and antivirulence agents against periodontal pathogens Fariza Abrão1, Thayná Souza Silva1, Claudia L. Moura1, Sérgio Ricardo Ambrósio2, Rodrigo Cassio Sola Veneziani2, Raphael E. F. de Paiva3, Jairo Kenupp Bastos4 & Carlos Henrique Gomes Martins1,5* Invasion of periodontal tissues by Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans can be associated with aggressive forms of periodontitis. Oleoresins from diferent copaifera species and their compounds display various pharmacological properties. The present study evaluates the antibacterial and antivirulence activity of oleoresins obtained from diferent copaifera species and of ten isolated compounds against two causative agents of periodontitis. The following assays were performed: determination of the minimum inhibitory concentration (MIC), determination of the minimum bactericidal concentration (MBC), and determination of the antibioflm activity by inhibition of bioflm formation and bioflm eradication tests. The antivirulence activity was assessed by hemagglutination, P. gingivalis Arg-X and Lis-X cysteine protease inhibition assay, and A. actinomycetemcomitans leukotoxin inhibition assay. The MIC and MBC of the oleoresins and isolated compounds 1, 2, and 3 ranged from 1.59 to 50 μg/ mL against P. gingivalis (ATCC 33277) and clinical isolates and from 6.25 to 400 μg/mL against A. actinomycetemcomitans (ATCC 43717) and clinical isolates. About the antibioflm activity, the oleoresins and isolated compounds 1, 2, and 3 inhibited bioflm formation by at least 50% and eradicated pre-formed P. gingivalis and A. actinomycetemcomitans bioflms in the monospecies and multispecies modes. A promising activity concerning cysteine protease and leucotoxin inhibition was also evident. In addition, molecular docking analysis was performed.
    [Show full text]
  • Non-Homologous Isofunctional Enzymes: a Systematic Analysis Of
    Omelchenko et al. Biology Direct 2010, 5:31 http://www.biology-direct.com/content/5/1/31 RESEARCH Open Access Non-homologousResearch isofunctional enzymes: A systematic analysis of alternative solutions in enzyme evolution Marina V Omelchenko, Michael Y Galperin*, Yuri I Wolf and Eugene V Koonin Abstract Background: Evolutionarily unrelated proteins that catalyze the same biochemical reactions are often referred to as analogous - as opposed to homologous - enzymes. The existence of numerous alternative, non-homologous enzyme isoforms presents an interesting evolutionary problem; it also complicates genome-based reconstruction of the metabolic pathways in a variety of organisms. In 1998, a systematic search for analogous enzymes resulted in the identification of 105 Enzyme Commission (EC) numbers that included two or more proteins without detectable sequence similarity to each other, including 34 EC nodes where proteins were known (or predicted) to have distinct structural folds, indicating independent evolutionary origins. In the past 12 years, many putative non-homologous isofunctional enzymes were identified in newly sequenced genomes. In addition, efforts in structural genomics resulted in a vastly improved structural coverage of proteomes, providing for definitive assessment of (non)homologous relationships between proteins. Results: We report the results of a comprehensive search for non-homologous isofunctional enzymes (NISE) that yielded 185 EC nodes with two or more experimentally characterized - or predicted - structurally unrelated proteins. Of these NISE sets, only 74 were from the original 1998 list. Structural assignments of the NISE show over-representation of proteins with the TIM barrel fold and the nucleotide-binding Rossmann fold. From the functional perspective, the set of NISE is enriched in hydrolases, particularly carbohydrate hydrolases, and in enzymes involved in defense against oxidative stress.
    [Show full text]
  • Quercetin Inhibits Virulence Properties of Porphyromas Gingivalis In
    www.nature.com/scientificreports OPEN Quercetin inhibits virulence properties of Porphyromas gingivalis in periodontal disease Zhiyan He1,2,3,7, Xu Zhang1,2,3,7, Zhongchen Song2,3,4, Lu Li5, Haishuang Chang6, Shiliang Li5* & Wei Zhou1,2,3* Porphyromonas gingivalis is a causative agent in the onset and progression of periodontal disease. This study aims to investigate the efects of quercetin, a natural plant product, on P. gingivalis virulence properties including gingipain, haemagglutinin and bioflm formation. Antimicrobial efects and morphological changes of quercetin on P. gingivalis were detected. The efects of quercetin on gingipains activities and hemolytic, hemagglutination activities were evaluated using chromogenic peptides and sheep erythrocytes. The bioflm biomass and metabolism with diferent concentrations of quercetin were assessed by the crystal violet and MTT assay. The structures and thickness of the bioflms were observed by confocal laser scanning microscopy. Bacterial cell surface properties including cell surface hydrophobicity and aggregation were also evaluated. The mRNA expression of virulence and iron/heme utilization was assessed using real time-PCR. Quercetin exhibited antimicrobial efects and damaged the cell structure. Quercetin can inhibit gingipains, hemolytic, hemagglutination activities and bioflm formation at sub-MIC concentrations. Molecular docking analysis further indicated that quercetin can interact with gingipains. The bioflm became sparser and thinner after quercetin treatment. Quercetin also modulate cell surface hydrophobicity and aggregation. Expression of the genes tested was down-regulated in the presence of quercetin. In conclusion, our study demonstrated that quercetin inhibited various virulence factors of P. gingivalis. Periodontal disease is a common chronic infammatory disease that characterized swelling and bleeding of the gums clinically, and leading to the progressive destruction of tooth-supporting tissues including the gingiva, alveolar bone, periodontal ligament, and cementum.
    [Show full text]
  • Propeptide-Mediated Inhibition of Cognate Gingipain Proteinases
    Propeptide-Mediated Inhibition of Cognate Gingipain Proteinases N. Laila Huq, Christine A. Seers, Elena C. Y. Toh, Stuart G. Dashper, Nada Slakeski, Lianyi Zhang, Brent R. Ward, Vincent Meuric, Dina Chen, Keith J. Cross, Eric C. Reynolds* Oral Health Cooperative Research Centre, Melbourne Dental School, Bio21 Institute of Molecular Science and Biotechnology, The University of Melbourne, Victoria, Australia Abstract Porphyromonas gingivalis is a major pathogen associated with chronic periodontitis. The organism’s cell-surface cysteine proteinases, the Arg-specific proteinases (RgpA, RgpB) and the Lys-specific proteinase (Kgp), which are known as gingipains have been implicated as major virulence factors. All three gingipain precursors contain a propeptide of around 200 amino acids in length that is removed during maturation. The aim of this study was to characterize the inhibitory potential of the Kgp and RgpB propeptides against the mature cognate enzymes. Mature Kgp was obtained from P. gingivalis mutant ECR368, which produces a recombinant Kgp with an ABM1 motif deleted from the catalytic domain (rKgp) that enables the otherwise membrane bound enzyme to dissociate from adhesins and be released. Mature RgpB was obtained from P. gingivalis HG66. Recombinant propeptides of Kgp and RgpB were produced in Escherichia coli and purified using nickel- affinity chromatography. The Kgp and RgpB propeptides displayed non-competitive inhibition kinetics with Ki values of 2.04 mM and 12 nM, respectively. Both propeptides exhibited selectivity towards their cognate proteinase. The specificity of both propeptides was demonstrated by their inability to inhibit caspase-3, a closely related cysteine protease, and papain that also has a relatively long propeptide.
    [Show full text]
  • Role of Coagulation Factor 2 Receptor During Respiratory Pneumococcal Infections
    Journal of Bacteriology and Virology 2016. Vol. 46, No. 4 p.319 – 325 http://dx.doi.org/10.4167/jbv.2016.46.4.319 Research Update (Minireview) Role of Coagulation Factor 2 Receptor during Respiratory Pneumococcal Infections * Seul Gi Shin1, Younghoon Bong2 and Jae Hyang Lim1 1Department of Microbiology, School of Medicine, Ewha Womans University, Seoul; 2College of Veterinary Medicine, Chonnam National University, Gwangju, Korea Coagulation factor 2 receptor (F2R), also well-known as a protease-activated receptor 1 (PAR1), is the first known thrombin receptor and plays a critical role in transmitting thrombin-mediated activation of intracellular signaling in many types of cells. It has been known that bacterial infections lead to activation of coagulation systems, and recent studies suggest that PAR1 may be critically involved not only in mediating bacteria-induced detrimental coagulation, but also in innate immune and inflammatory responses. Community-acquired pneumonia, which is frequently caused by Streptococcus pneumoniae (S. pneumoniae), is characterized as an intra-alveolar coagulation and an interstitial neutrophilic inflammation. Recently, the role of PAR1 in regulating pneumococcal infections has been proposed. However, the role of PAR1 in pneumococcal infections has not been clearly understood yet. In this review, recent findings on the role of PAR1 in pneumococcal infections and possible underlying molecular mechanisms by which S. pneumoniae regulates PAR1- mediated immune and inflammatory responses will be discussed. Key Words: Streptococcus pneumoniae, Coagulation factor 2 receptor, F2R, Protease-activated receptor 1, PAR1 mation (8). Lung injury at the early stage of infection is INTRODUCTION critical step to initiate intravascular dissemination of pneumo- coccus and develop detrimental systemic infections, such as Community-acquired pneumonia (CAP) is a major cause bacteremia, meningitis, arthritis, and septicemia (8).
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Characterisation of Inflammatory Responses in Two Models of Experimental Ischaemia
    CHARACTERISATION OF INFLAMMATORY RESPONSES IN TWO MODELS OF EXPERIMENTAL ISCHAEMIA Louise Marks, April 2001 A thesis submitted for the degree of Doctor of Philosophy to the Faculty of Medicine, University of Glasgow. Wellcome Surgical Institute and Hugh Fraser Neuroscience Laboratories, University of Glasgow, Bearsden Road, Glasgow, G61 1QH. UNIVERSITY GLASGOW ProQuest Number: 13833994 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833994 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 \lbl2 0)P1\ II Contents Title page page I Contents page n List of tables page VIII List of figures page IX Abbreviations page XIV Acknowledgements page XVI Authors declaration page XVH Summary page XVIII Chapter 1. Introduction page 1 1.1 Stroke Background page 1 1.1.1 Stroke facts and figures page 1 1.1.2 Ischaemia and stroke page 1 1.2 Classification of stroke page 2 1.2.1 Haemorrhagic stroke page 3 1.2.2 Ischaemic stroke page 3 1.3 Models of cerebral ischaemia page 4 1.3.1 Use of the rat as a model of cerebral
    [Show full text]
  • The Role of Tannerella Forsythia and Porphyromonas Gingivalis in Pathogenesis of Esophageal Cancer Bartosz Malinowski1, Anna Węsierska1, Klaudia Zalewska1, Maya M
    Malinowski et al. Infectious Agents and Cancer (2019) 14:3 https://doi.org/10.1186/s13027-019-0220-2 REVIEW Open Access The role of Tannerella forsythia and Porphyromonas gingivalis in pathogenesis of esophageal cancer Bartosz Malinowski1, Anna Węsierska1, Klaudia Zalewska1, Maya M. Sokołowska1, Wiktor Bursiewicz1*, Maciej Socha3, Mateusz Ozorowski1, Katarzyna Pawlak-Osińska2 and Michał Wiciński1 Abstract Tannerella forsythia and Porphyromonas gingivalis are anaerobic, Gram-negative bacterial species which have been implicated in periodontal diseases as a part of red complex of periodontal pathogens. Esophageal cancer is the eight most common cause of cancer deaths worldwide. Higher rates of esophageal cancer cases may be attributed to lifestyle factors such as: diet, obesity, alcohol and tobacco use. Moreover, the presence of oral P. gingivalis and T. forsythia has been found to be associated with an increased risk of esophageal cancer. Our review describes theroleofP. gingivalis and T. forsythia in signaling pathways responsible for cancer development. It has been shown that T. forsythia may induce pro-inflammatory cytokines such as IL-1β and IL-6 by CD4 + T helper cells and TNF-α. Moreover, gingipain K produced by P. gingivalis, affects hosts immune system by degradation of immunoglobulins and complement system (C3 and C5 components). Discussed bacteria are responsible for overexpression of MMP-2, MMP-2 and GLUT transporters. Keywords: Esophageal cancer, Tannerella forsythia, Porphyromonas gingivalis Background of cases) and adenocarcinoma (10%). Currently, there is a Cancer is a significant problem in the modern world. It downward trend in the incidence of squamous cell carcin- concerns the entire population. In developed countries, oma and an increase in adenocarcinoma [1].
    [Show full text]
  • Crystallization and Structure Analysis
    Electronic Supplementary Material (ESI) for Chemical Science This journal is © The Royal Society of Chemistry 2013 1 ELECTRONIC SUPPLEMENTARY INFORMATION Table of Contents 1. Experimental procedures 1 Production and purification of sermetstatin 1 Production and purification of snapalysin 2 In vitro activation studies of prosnapalysin 3 Proteolytic and inhibition assays 4 Cleavage of sermetstatin mutants 4 Complex formation and purification 5 Crystallization and X-ray diffraction data collection 5 Structure solution and refinement 6 Miscellaneous 8 2. Acknowledgments 8 3. Supplemental References 9 4. Supplemental Tables 11 Supplemental Table S1 11 Supplemental Table S2 12 Supplemental Table S3 13 5. Supplemental Figures 14 Supplemental Figure S1 14 1. Experimental procedures Production and purification of sermetstatin – A synthetic gene coding for sermetstatin from Streptomyces caespitosus (UniProt database code Q9FDS0), also known as Streptomyces caespitosus neutral proteinase inhibitor 1, was purchased (GenScript) and cloned into a modified pET-32a vector between the BglII and HindIII restriction sites. This vector attaches an N-terminal thioredoxin-His6 fusion construct followed by a tobacco-etch-virus (TEV) protease recognition site. Sermetstatin was produced by heterologous overexpression in Escherichia coli Origami2 (DE3) cells (Novagen). These were grown at 37°C in Luria-Bertani (LB) medium containing 100µg/ml ampicillin and 10µg/ml tetracycline, induced at an OD550 of 0.6 with isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.25mM, and subsequently incubated overnight at 18°C. Cultures were centrifuged at 7,000xg for 30min at 4°C. Pellets were washed twice with buffer A (50mM Tris-HCl, 500mM NaCl, pH8.0) and resuspended in the same buffer further containing 20mM imidazole and supplemented with EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics) and DNase I (Roche Diagnostics).
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • ^ P X R, for the PURPOSES of INFORMATION ONLY
    WORLD INTELLECTUAL PROPERTY ORGANIZATION PCT International Bureau INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 6 : (11) International Publication Number: WO 98/49190 C07K 5/06, 5/08, 5/10 A l (43) International Publication Date: 5 November 1998 (05.11.98) (21) International Application Number: PCT/US98/08259 (74) Agents: BURKE, John, E. et al.; Cushman Darby & Cushman, Intellectual Property Group of Pillsbury Madison & Sutro, (22) International Filing Date: 24 April 1998 (24.04.98) 1100 New York Avenue, N.W., Washington, DC 20005 (US). (30) Priority Data: 60/044,819 25 April 1997 (25.04.97) US (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, Not furnished 23 April 1998 (23.04.98) US BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, (71) Applicant (for all designated States except US): CORTECH, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, INC. [US/US]; 6850 North Broadway, Denver, CO 80221 TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO (US). patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (72) Inventors; and patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, (75) Inventors/Applicants(for US only): SPRUCE, Lyle, W. IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, [US/US]; 948 Camino Del Sol, Chula Vista, CA 91910 CG, Cl, CM, GA, GN, ML, MR, NE, SN, TD, TG).
    [Show full text]